Skip to main content
SpringerLink
Log in

Current treatment of chronic HBV infection: An Asian-Pacific perspective

  • Published:
Current Hepatitis Reports Aims and scope Submit manuscript

Abstract

Chronic hepatitis B virus (HBV) infection is a major global health problem with potential adverse sequelae including liver cirrhosis and hepatocellular carcinoma. Of more than 350 million chronic HBV carriers, 75% reside in the Asian-Pacific region, where most countries have low-income economies. Better understanding of the natural history and immunopathogenesis of chronic HBV infection and the invention of powerful antiviral agents have improved the therapeutic strategy. Guidelines issued by major liver associations are basically similar. However, each country in the Asian-Pacific region has specific problems. Because cost is a main concern, drugs with low genetic barrier to resistance are still widely used in these countries. Modifications needed to accommodate specific situations and problems include more stringent indications for drug therapy, starting therapy with the least expensive drug, and defining stopping rules even for hepatitis B e antigen-negative patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Liaw YF, Chu CM: Hepatitis B virus infection. Lancet 2009, 373:582–592.

    Article  CAS  PubMed  Google Scholar 

  2. Fattovich G. Bortolotti F, Donato F: Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008, 48:335–352.

    Article  PubMed  Google Scholar 

  3. Liaw YF: Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009, 29(Suppl 1):100–107.

    Article  PubMed  Google Scholar 

  4. Zoulim F, Perrillo R: Hepatitis B: reflection on the current approach to antiviral therapy. J Hepatol 2008, 48:S2–S19.

    Article  CAS  PubMed  Google Scholar 

  5. Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007, 45:507–539.

    Article  CAS  PubMed  Google Scholar 

  6. Liaw YF, Leung N, Kao JH, et al.: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008, 2:263–283.

    Article  PubMed  Google Scholar 

  7. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227–242.

    Article  CAS  PubMed  Google Scholar 

  8. ACT-HBV Asia-Pacific Steering Committee Members: Chronic hepatitis B: treatment alert. Liver International 2006, 26(Suppl 2):47–58.

    Article  Google Scholar 

  9. Keeffe EB, Dieterich DT, Han SH, et al.: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008, 6:1315–1341.

    Article  CAS  PubMed  Google Scholar 

  10. Liaw YF: Antiviral therapies of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol 2009, 51:403–410.

    Article  PubMed  Google Scholar 

  11. Kao JH: Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int 2007, 1:415–430.

    Article  PubMed  Google Scholar 

  12. Hui CK, Leung N, Yuen ST, et al.: Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007, 46:395–401.

    Article  PubMed  Google Scholar 

  13. Hsu YS, Chien RN, Yeh CT, et al.: Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002, 35:1522–1527.

    Article  PubMed  Google Scholar 

  14. Chu CM, Liaw YF: Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 2006, 26:142–152.

    Article  CAS  PubMed  Google Scholar 

  15. Chen YC, Chu CM, Yeh CT, Liaw YF: Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int 2007, 1:267–273.

    Article  PubMed  Google Scholar 

  16. Chen CJ, Yang HI, Su J, et al.: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65–73.

    Article  CAS  PubMed  Google Scholar 

  17. Iloeje UH, Yang HI, Su J, et al.: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678–686.

    Article  PubMed  Google Scholar 

  18. Yang HI, Yeh SH, Chen PJ, et al.; REVEAL-HBV Study Group: Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:1134–1143.

    Article  CAS  PubMed  Google Scholar 

  19. Chu CM, Liaw YF: Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat 2007, 14:147–152.

    Article  PubMed  Google Scholar 

  20. Liaw YF: Hepatitis B virus replication and liver disease progression: The impact of antiviral therapy. Antivir Ther 2006, 11:669–679.

    CAS  PubMed  Google Scholar 

  21. Liaw YF, Lin SM, Chen TJ, et al.: Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: a randomised controlled trial. J Hepatol 1994, 20:175–180.

    Article  CAS  PubMed  Google Scholar 

  22. Lok AS, Wu PC, Lai CL, et al.: A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992, 102:2091–2097.

    CAS  PubMed  Google Scholar 

  23. Mellerup MT, Krogsgaard K, Mathurin P, et al.: Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B. Cochrane Database Syst Rev 2005, 3:CD000345.

    PubMed  Google Scholar 

  24. Lin CC, Wu JC, Chang TT, et al.: Long-term evaluation of recombinant interferon alpha2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan. J Viral Hepat 2001, 8:438–446.

    Article  CAS  PubMed  Google Scholar 

  25. Lin SM, Yu ML, Lee CM, et al.: Interferon therapy in HBeAg positive chronic hepatitis reduces cirrhosis and hepatocellular carcinoma. J Hepatol 2007, 46:45–52.

    Article  CAS  PubMed  Google Scholar 

  26. Niederau C, Heintges T, Lange S, et al.: Long-term followup of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996, 334:1422–1427.

    Article  CAS  PubMed  Google Scholar 

  27. Papatheodoridis GV, Manesis E, Hadziyannis SJ: The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001, 34:306–313.

    Article  CAS  PubMed  Google Scholar 

  28. Sung JJ, Tsoi KK, Wong VW, et al.: Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008, 28:1067–1077.

    Article  CAS  PubMed  Google Scholar 

  29. Cooksley WGF, Piratvisuth T, Lee SD, et al.: Peginterferon alpha 2a(40kDa): an advance in the treatment of hepatitis Be antigen-positive chronic hepatitis B. J Viral Hepat 2003, 10:298–305.

    Article  CAS  PubMed  Google Scholar 

  30. Lau GK, Piratvisuth T, Luo KX, et al.: Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352:2682–2695.

    Article  CAS  PubMed  Google Scholar 

  31. Piratvisuth T, Lau G, Chao YC, et al.: Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int 2008, 2:102–110.

    Article  PubMed  Google Scholar 

  32. Janssen HLA, van Zonneveld M, Senturk H, et al.: Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005, 365:123–129.

    Article  CAS  PubMed  Google Scholar 

  33. Marcellin P, Chang TT, Lim SG, et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003, 348:808–816.

    Article  CAS  PubMed  Google Scholar 

  34. Chien RN, Liaw YF: Thymalfasin for the treatment of chronic hepatitis B. Expert Rev Anti-Infect Ther 2004, 2:9–16.

    Article  CAS  PubMed  Google Scholar 

  35. Chien RN, Liaw YF, Chen TC, et al.: Efficacy of thymosin alpha-1 in patients with chronic type B hepatitis: a randomized controlled trial. Hepatology 1998, 27:1383–1387.

    Article  CAS  PubMed  Google Scholar 

  36. Chan HLY, Tang JL, Tam W, Sung JJY: The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a metaanalysis. Aliment Pharmacol Ther 2001, 15:1899–1905.

    Article  CAS  PubMed  Google Scholar 

  37. Yang YF, Zhao W, Zhong YD, et al.: Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis. Antivir Res 2008, 77:136–141.

    Article  CAS  PubMed  Google Scholar 

  38. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131:1743–1751.

    Article  CAS  PubMed  Google Scholar 

  39. Lai CL, Shouval D, Lok AS, et al.: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354:1011–1020.

    Article  CAS  PubMed  Google Scholar 

  40. Gish RG, Lok AS, Chang TT, et al.: Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007, 133:1437–1444.

    Article  CAS  PubMed  Google Scholar 

  41. Lai CL, Gane E, Liaw YF, et al.: A comparison of telbivudine and lamivudine in patients with chronic hepatitis B. N Engl J Med 2007, 357:34–46.

    Article  Google Scholar 

  42. Tassopoulos NC, Volpes R, Pastore G, et al.: Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999, 29:889–896.

    Article  CAS  PubMed  Google Scholar 

  43. Chien RN, Liaw YF: Short term lamivudine therapy in active HBeAg-negative chronic hepatitis B patients in Taiwan. Antivir Ther 2006, 11:947–952.

    CAS  PubMed  Google Scholar 

  44. Liaw YF, Chien RN, Yeh CT, et al.: Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999, 30:567–572.

    Article  CAS  PubMed  Google Scholar 

  45. Liaw YF, Sung JJY, Chow WC, et al.: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521–1531.

    Article  CAS  PubMed  Google Scholar 

  46. Di Marco V, Marzano A, Lampertico P, et al.: Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004, 40:883–891.

    Article  PubMed  Google Scholar 

  47. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al.: Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005, 42:121–129.

    Article  CAS  PubMed  Google Scholar 

  48. Chien RN, Liaw YF: Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol 2008, 22:1081–1092.

    Article  CAS  PubMed  Google Scholar 

  49. Lampertico P, Viganò M, Manenti E, et al.: Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007, 133:1445–1451.

    Article  CAS  PubMed  Google Scholar 

  50. Liaw YF: On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future. Antivir Ther 2009, 14:13–22.

    CAS  PubMed  Google Scholar 

  51. Flink HJ, Hansen BE, Heathcote EJ, et al.: Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. Am J Gastroenterol 2006, 101:2523–2529.

    Article  CAS  PubMed  Google Scholar 

  52. Liaw YF: Management of patients with chronic hepatitis B and cirrhosis. Curr Hepatitis Rep 2007, 6:161–165.

    Google Scholar 

  53. Yuen MF, Seto WK, Chow DHF, et al.: Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007, 12:1295–1303.

    CAS  PubMed  Google Scholar 

  54. Matsumoto A, Tanaka E, Rokuhara A, et al.: Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res 2005, 32:173–184.

    Article  CAS  PubMed  Google Scholar 

  55. Chien RN, Yeh CT, Tsai SL, et al.: The determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003, 38:1267–1273.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chang Gung Memorial Hospital and University, 199 Tung Hua North Road, Taipei, Taiwan

    Yun-Fan Liaw

Authors
  1. Rong-Nan Chien
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yun-Fan Liaw
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yun-Fan Liaw.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chien, RN., Liaw, YF. Current treatment of chronic HBV infection: An Asian-Pacific perspective. Curr hepatitis rep 8, 154–160 (2009). https://doi.org/10.1007/s11901-009-0022-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-009-0022-x

Keywords

Search

Navigation